ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ACAD
- CUSIP: N/A
- Web: www.acadia-pharm.com
Capitalization:- Market Cap: $4.51045 billion
- Outstanding Shares: 122,400,000
Average Prices:- 50 Day Moving Avg: $33.31
- 200 Day Moving Avg: $31.51
- 52 Week Range: $20.68 - $40.83
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -19.39
- P/E Growth: -0.49
Sales & Book Value:- Annual Revenue: $62.99 million
- Price / Sales: 71.61
- Book Value: $3.39 per share
- Price / Book: 10.87
Profitability:- EBIDTA: ($305,320,000.00)
- Net Margins: -485.14%
- Return on Equity: -62.08%
- Return on Assets: -57.18%
Debt:- Current Ratio: 10.85%
- Quick Ratio: 10.70%
Misc:- Average Volume: 1.46 million shs.
- Beta: 3.9
- Short Ratio: 13.54
Frequently Asked Questions for ACADIA Pharmaceuticals (NASDAQ:ACAD)
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its earnings results on Tuesday, August, 8th. The company reported ($0.55) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.72) by $0.17. The firm earned $30.50 million during the quarter, compared to the consensus estimate of $20.02 million. ACADIA Pharmaceuticals had a negative return on equity of 62.08% and a negative net margin of 485.14%. The business's quarterly revenue was up 30400.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.63) earnings per share. View ACADIA Pharmaceuticals' Earnings History.
When will ACADIA Pharmaceuticals make its next earnings announcement?
Where is ACADIA Pharmaceuticals' stock going? Where will ACADIA Pharmaceuticals' stock price be in 2017?
12 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' stock. Their predictions range from $25.00 to $60.00. On average, they expect ACADIA Pharmaceuticals' share price to reach $44.17 in the next year. View Analyst Ratings for ACADIA Pharmaceuticals.
What are analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (8/11/2017)
- 2. Needham & Company LLC analysts commented, "Acadia reported $11.9M in 4Q16 Nuplazid sales, above our $9.0M estimate. Mgmt noted steady growth in number of prescribers, repeat prescribers, and new patients. Company also announced plan to expand sales force by 20 reps to address long-term care opportunity. There are no immediate plans to provide 2017 sales guidance. We believe stock is attractive given Nuplazid launch trajectory and likelihood for label expansion in long-term. Stock likely to be driven by sales in 2017 and Phase 2/3 results in other indications in 2018/ 2019. Acadia may be an attractive M&A target. BUY." (3/1/2017)
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), ICON PLC (ICLR), INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), United Therapeutics Corporation (UTHR), Charles River Laboratories International (CRL), PRA Health Sciences (PRAH), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX) and Portola Pharmaceuticals (PTLA).
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Stephen R. Biggar M.D. Ph.D., Chairman of the Board
- Stephen R. Davis, President, Chief Executive Officer, Director
- Todd S. Young, Executive Vice President, Chief Financial Officer
- Glenn F. Baity, Executive Vice President, General Counsel, Secretary
- Srdjan Stankovic M.D., Executive Vice President, Head - Research and Development
- Michael J. Yang, Executive Vice President, Chief Commercial Officer
- Edmund P. Harrigan M.D., Director
- Julian C. Baker, Independent Director
- Laura A. Brege, Independent Director
- James M. Daly, Independent Director
Who owns ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (15.00%), Vanguard Group Inc. (6.23%), BlackRock Inc. (4.58%), State Street Corp (3.06%), Janus Henderson Group PLC (2.99%) and Franklin Resources Inc. (2.93%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Edmund Harrigan, Glenn Baity, Leslie L Iversen, LP 14159 and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Who sold ACADIA Pharmaceuticals stock? Who is selling ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including AXA, Franklin Resources Inc., Dai Ichi Life Insurance Company Ltd, Alliancebernstein L.P., TD Asset Management Inc., Parametric Portfolio Associates LLC, Raymond James Financial Services Advisors Inc. and California State Teachers Retirement System. Company insiders that have sold ACADIA Pharmaceuticals stock in the last year include Glenn Baity and Terrence O Moore. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Who bought ACADIA Pharmaceuticals stock? Who is buying ACADIA Pharmaceuticals stock?
ACADIA Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Goldman Sachs Group Inc., First Trust Advisors LP, State Street Corp, Elliott Management Corp, Sectoral Asset Management Inc, NF Trinity Capital Hong Kong Ltd and Pictet Asset Management Ltd.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker, Edmund Harrigan and LP 14159. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy ACADIA Pharmaceuticals stock?
Shares of ACADIA Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACADIA Pharmaceuticals stock can currently be purchased for approximately $36.85.
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for ACADIA Pharmaceuticals (NASDAQ:ACAD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.75) |
| Consensus Price Target: | $44.17 (19.86% upside) |
Analysts' Ratings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/17/2017 | Needham & Company LLC | Reiterated Rating | Buy | $49.00 | Low |  |
| 8/9/2017 | Piper Jaffray Companies | Set Price Target | Buy | $54.00 | High | |
| 8/10/2017 | Cowen and Company | Reiterated Rating | Outperform | $42.00 -> $46.00 | High | |
| 8/9/2017 | HC Wainwright | Reiterated Rating | Buy | $60.00 | High | |
| 5/22/2017 | Rodman & Renshaw | Reiterated Rating | Buy | $60.00 | Low | |
| 4/12/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $47.00 | Low | |
| 2/2/2017 | Ladenburg Thalmann Financial Services | Initiated Coverage | Buy -> Buy | $49.00 -> $48.00 | N/A | |
| 1/11/2017 | J P Morgan Chase & Co | Reiterated Rating | Buy | | N/A | |
| 12/28/2016 | Leerink Swann | Reiterated Rating | Market Perform | $29.00 | N/A | |
| 11/11/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $28.00 | N/A | |
| 11/8/2016 | Bank of America Corporation | Upgrade | Neutral -> Buy | $35.00 | N/A | |
| 10/19/2016 | Roth Capital | Reiterated Rating | Neutral | $25.00 | N/A | |
| 8/10/2016 | JMP Securities | Reiterated Rating | Buy | $45.00 | N/A | |
| 8/5/2016 | Aegis | Downgrade | Buy -> Hold | $54.00 -> $41.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for ACADIA Pharmaceuticals (NASDAQ:ACAD)Earnings History by Quarter for ACADIA Pharmaceuticals (NASDAQ ACAD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | ($0.63) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($0.72) | ($0.55) | $20.02 million | $30.50 million | View | Listen | |
| 5/9/2017 | Q1 2017 | ($0.73) | ($0.72) | $15.17 million | $15.30 million | View | Listen | |
| 2/28/2017 | Q416 | ($0.65) | ($0.65) | $9.05 million | $12.00 million | View | Listen | |
| 11/7/2016 | Q316 | ($0.56) | ($0.61) | $2.90 million | $5.30 million | View | Listen | |
| 8/4/2016 | Q216 | ($0.49) | ($0.63) | $0.71 million | $0.97 million | View | Listen | |
| 5/5/2016 | Q116 | ($0.42) | ($0.45) | $0.22 million | | View | Listen | |
| 2/29/2016 | Q415 | ($0.38) | ($0.45) | | $0.02 million | View | Listen | |
| 11/5/2015 | Q315 | ($0.40) | ($0.39) | $0.05 million | $0.04 million | View | Listen | |
| 8/6/2015 | Q215 | ($0.33) | ($0.39) | $0.06 million | | View | Listen | |
| 5/7/2015 | Q115 | ($0.25) | ($0.40) | $0.09 million | | View | Listen | |
| 2/26/2015 | Q414 | ($0.26) | ($0.28) | $0.08 million | $0.05 million | View | Listen | |
| 11/10/2014 | Q3 | ($0.12) | ($0.25) | | $0.02 million | View | Listen | |
| 8/5/2014 | Q2 | ($0.17) | ($0.22) | $0.10 million | $0.03 million | View | Listen | |
| 5/6/2014 | Q1 | ($0.13) | ($0.19) | $0.50 million | $0.03 million | View | Listen | |
| 2/27/2014 | Q4 | ($0.14) | ($0.13) | | | View | Listen | |
| 8/6/2013 | Q2 2013 | ($0.09) | ($0.11) | $0.45 million | $451.00 million | View | Listen | |
| 5/7/2013 | Q1 2013 | ($0.08) | ($0.08) | $0.45 million | $0.42 million | View | Listen | |
| 11/5/2012 | Q312 | ($0.09) | ($0.04) | $1.90 million | $3.50 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for ACADIA Pharmaceuticals (NASDAQ:ACAD)2017 EPS Consensus Estimate: ($2.28)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.75) | ($0.53) | ($0.64) |
| Q2 2017 | 2 | ($0.71) | ($0.48) | ($0.60) |
| Q3 2017 | 2 | ($0.64) | ($0.44) | ($0.54) |
| Q4 2017 | 2 | ($0.62) | ($0.39) | ($0.51) |
(Data provided by Zacks Investment Research)
Dividend History for ACADIA Pharmaceuticals (NASDAQ:ACAD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ACADIA Pharmaceuticals (NASDAQ:ACAD)Insider Ownership Percentage: 22.25%
Institutional Ownership Percentage: 97.10%
Insider Trades by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/30/2017 | Glenn Baity | EVP | Sell | 26,507 | $34.87 | $924,299.09 | |
| 8/9/2017 | Glenn Baity | EVP | Sell | 14,322 | $34.88 | $499,551.36 | |
| 7/20/2017 | Glenn Baity | EVP | Sell | 38,097 | $30.00 | $1,142,910.00 | |
| 6/22/2017 | Glenn Baity | EVP | Sell | 1,903 | $30.00 | $57,090.00 | |
| 2/16/2017 | Terrence O. Moore | EVP | Sell | 157,540 | $39.77 | $6,265,365.80 | |
| 12/27/2016 | Glenn Baity | EVP | Sell | 9,800 | $30.46 | $298,508.00 | |
| 12/20/2016 | Glenn Baity | EVP | Sell | 10,000 | $30.00 | $300,000.00 | |
| 8/16/2016 | Edmund Harrigan | Director | Buy | 1,000 | $32.97 | $32,970.00 | |
| 8/10/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,303,030 | $33.00 | $42,999,990.00 | |
| 7/12/2016 | Glenn Baity | EVP | Sell | 16,000 | $35.00 | $560,000.00 | |
| 7/11/2016 | Glenn Baity | EVP | Sell | 4,057 | $35.00 | $141,995.00 | |
| 4/18/2016 | Leslie L Iversen | Director | Sell | 33,697 | $33.53 | $1,129,860.41 | |
| 4/1/2016 | Bros. Advisors Lp Baker | Director | Buy | 1,449,090 | $27.08 | $39,241,357.20 | |
| 1/7/2016 | L.P. 14159 | Director | Buy | 2,586,206 | $29.00 | $74,999,974.00 | |
| 11/11/2015 | Leslie L. Iversen | Director | Sell | 30,000 | $36.01 | $1,080,300.00 | |
| 1/15/2015 | Michael T Borer | Director | Sell | 27,973 | $33.02 | $923,668.46 | |
| 1/14/2015 | Uli Hacksell | CEO | Sell | 30,000 | $33.98 | $1,019,400.00 | |
| 12/15/2014 | Mary Ann Gray | Director | Sell | 12,250 | $31.74 | $388,815.00 | |
| 12/15/2014 | Uli Hacksell | CEO | Sell | 30,000 | $31.00 | $930,000.00 | |
| 11/26/2014 | Michael T Borer | Director | Sell | 15,000 | $30.05 | $450,750.00 | |
| 11/26/2014 | Roger Mills | CMO | Sell | 25,000 | $30.09 | $752,250.00 | |
| 11/24/2014 | Uli Hacksell | CEO | Sell | 30,000 | $29.28 | $878,400.00 | |
| 11/21/2014 | William Mcdowall Wells | Director | Sell | 5,810 | $29.00 | $168,490.00 | |
| 10/8/2014 | Uli Hacksell | CEO | Sell | 30,000 | $24.15 | $724,500.00 | |
| 9/15/2014 | Laura Brege | Director | Sell | 10,000 | $28.07 | $280,700.00 | |
| 9/12/2014 | William Mcdowall Wells | Director | Sell | 9,190 | $29.15 | $267,888.50 | |
| 9/10/2014 | Uli Hacksell | CEO | Sell | 30,000 | $27.36 | $820,800.00 | |
| 8/15/2014 | Uli Hacksell | CEO | Sell | 15,000 | $22.89 | $343,350.00 | |
| 7/14/2014 | Uli Hacksell | CEO | Sell | 20,000 | $22.22 | $444,400.00 | |
| 6/16/2014 | Uli Hacksell | CEO | Sell | 20,000 | $23.10 | $462,000.00 | |
| 6/9/2014 | William Mcdowall Wells | Director | Sell | 15,000 | $23.03 | $345,450.00 | |
| 5/1/2014 | Torsten Rasmussen | Director | Sell | 32,857 | $20.03 | $658,125.71 | |
| 4/15/2014 | Uli Hacksell | CEO | Sell | 25,000 | $17.75 | $443,750.00 | |
| 4/4/2014 | Thomas Aasen | CFO | Sell | 15,000 | $22.48 | $337,200.00 | |
| 4/4/2014 | Torsten Rasmussen | Director | Sell | 30,000 | $21.98 | $659,400.00 | |
| 3/5/2014 | Bros. Advisors Lp Baker | Director | Buy | 526,316 | $28.50 | $15,000,006.00 | |
| 2/26/2014 | Glenn Baity | VP | Sell | 42,000 | $30.28 | $1,271,760.00 | |
| 11/1/2013 | Torsten Rasmussen | Director | Sell | 37,692 | $23.00 | $866,916.00 | |
| 11/1/2013 | Uli Hacksell | CEO | Sell | 15,000 | $23.24 | $348,600.00 | |
| 10/10/2013 | Laura Brege | Director | Sell | 10,000 | $21.63 | $216,300.00 | |
| 10/1/2013 | Thomas H Aasen | CFO | Sell | 30,000 | $27.87 | $836,100.00 | |
| 9/20/2013 | Roger Mills | CMO | Sell | 35,965 | $25.01 | $899,484.65 | |
| 9/12/2013 | Lester Ph Kaplan | Director | Sell | 66,356 | $22.90 | $1,519,552.40 | |
| 9/10/2013 | Laura Brege | Director | Sell | 46,153 | $22.80 | $1,052,288.40 | |
| 9/3/2013 | Torsten Rasmussen | Director | Sell | 40,000 | $20.28 | $811,200.00 | |
| 8/26/2013 | Mary Ann Gray | Director | Sell | 15,000 | $20.68 | $310,200.00 | |
| 8/13/2013 | Thomas Aasen | CFO | Sell | 60,000 | $20.15 | $1,209,000.00 | |
| 8/13/2013 | Uli Hacksell | CEO | Sell | 52,771 | $20.14 | $1,062,807.94 | |
| 6/5/2013 | Felix Baker | Director | Buy | 2,340,314 | $14.34 | $33,560,102.76 | |
| 5/15/2013 | Felix Baker | Director | Buy | 1,993,000 | $12.50 | $24,912,500.00 | |
| 4/12/2013 | Glenn Baity | VP | Sell | 60,000 | $12.42 | $745,200.00 | |
| 4/11/2013 | Thomas H Aasen | CFO | Sell | 40,000 | $11.06 | $442,400.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for ACADIA Pharmaceuticals (NASDAQ:ACAD)
Latest Headlines for ACADIA Pharmaceuticals (NASDAQ:ACAD)
| Source: |
|
| Date | Headline |
|---|
 | Head-To-Head Contrast: INC Research Holdings (INCR) & ACADIA Pharmaceuticals (ACAD)
www.americanbankingnews.com - September 21 at 12:44 AM |
 | Technical Reports on Biotech Equities -- Vanda Pharma, ACADIA Pharma, Achillion Pharma, and Agios Pharma - PR Newswire (press release)
www.prnewswire.com - September 20 at 3:17 PM |
 | Acadia: Where's The Upside From Current Levels? - Seeking Alpha
seekingalpha.com - September 20 at 3:17 PM |
 | Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
finance.yahoo.com - September 19 at 8:24 PM |
| Supernus Drops SPN-810's Lower Dose Test in Phase III Trials
finance.yahoo.com - September 19 at 8:23 PM |
 | ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann ... - Business Wire (press release)
www.businesswire.com - September 19 at 3:23 PM |
| ACADIA Pharmaceuticals to Present at the Ladenburg Thalmann 2017 Healthcare Conference on September 26, 2017
finance.yahoo.com - September 19 at 3:23 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Expected to Post Quarterly Sales of $31.52 Million
www.americanbankingnews.com - September 18 at 4:48 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Receives "Buy" Rating from Needham & Company LLC
www.americanbankingnews.com - September 17 at 8:48 AM |
| Zacks: Analysts Expect ACADIA Pharmaceuticals Inc. (ACAD) to Post -$0.63 EPS
www.americanbankingnews.com - September 16 at 6:28 PM |
| Head-To-Head Review: ACADIA Pharmaceuticals (ACAD) & PAREXEL International Corporation (PRXL)
www.americanbankingnews.com - September 16 at 4:10 PM |
| Alexion (ALXN) Reports Interim Results for Soliris Study
finance.yahoo.com - September 14 at 3:20 PM |
| Acadia Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers
seekingalpha.com - September 12 at 3:20 PM |
| Marinus Stock Surges on Successful Phase II Epilepsy Study
finance.yahoo.com - September 12 at 3:20 PM |
| Today's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and Clovis Oncology
finance.yahoo.com - September 11 at 3:58 PM |
| Nuplazid Sees Increasing Physician Intent to Prescribe in 2017
finance.yahoo.com - September 8 at 8:38 PM |
| Nuplazid for Long-Term Care: Revenue Driver for Acadia?
finance.yahoo.com - September 8 at 8:38 PM |
| Nuplazid Expected to Become a Leading Central Nervous System Drug
finance.yahoo.com - September 8 at 3:35 PM |
| Acadia Could Report Robust Revenue Growth in 2017
finance.yahoo.com - September 7 at 3:18 PM |
| Merck (MRK) Opts for Buying German Immuno-Oncology Biotech
finance.yahoo.com - September 7 at 3:18 PM |
| ETFs with exposure to ACADIA Pharmaceuticals, Inc. : September 7, 2017
finance.yahoo.com - September 7 at 3:18 PM |
| BioMarin Presents Interim Data on BMN 250 from Phase I/II
finance.yahoo.com - September 7 at 3:18 PM |
| ACADIA Pharmaceuticals, Inc. :ACAD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
finance.yahoo.com - September 5 at 3:31 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Lifted to Hold at ValuEngine
www.americanbankingnews.com - September 4 at 12:00 AM |
| Insider Selling: ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells 26,507 Shares of Stock
www.americanbankingnews.com - September 1 at 7:20 PM |
| Stocks To Watch: Acadia Pharmaceuticals Sees RS Rating Jump To 83
finance.yahoo.com - August 30 at 3:23 PM |
| FDA's Refusal-to-File Letter for Inbrija Pushes Acorda Down
finance.yahoo.com - August 30 at 3:23 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - August 30 at 2:32 PM |
| ACADIA Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers - Seeking Alpha
seekingalpha.com - August 29 at 3:43 PM |
| ACADIA Stock Recovers From Recent Slump, Posts Strong Quarterly Numbers - Seeking Alpha
seekingalpha.com - August 29 at 3:43 PM |
 | Adamas Pharma's Gocovri Approved, A Welcome Addition To Parkinson's Treatments - Benzinga
www.benzinga.com - August 25 at 4:58 PM |
| Kite Pharma at New 52-Week High: What's Driving the Stock?
finance.yahoo.com - August 24 at 3:21 PM |
| Ultragenyx (RARE) Posts Disappointing Phase III Ace-ER Data
finance.yahoo.com - August 23 at 8:23 PM |
| Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer
finance.yahoo.com - August 18 at 3:21 PM |
 | Acadia Pharmaceuticals Has Huge Opportunities Ahead
www.investopedia.com - August 15 at 8:46 PM |
 | Big-Name US Hedge Funds Shed Healthcare Stocks During the Rally in Second Quarter - New York Times
www.nytimes.com - August 14 at 3:29 PM |
| $29.03 Million in Sales Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter
www.americanbankingnews.com - August 12 at 5:38 AM |
| ACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - August 11 at 9:46 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) EVP Sells $499,551.36 in Stock
www.americanbankingnews.com - August 11 at 7:52 PM |
| Q3 2017 EPS Estimates for ACADIA Pharmaceuticals Inc. Raised by Analyst (ACAD)
www.americanbankingnews.com - August 11 at 10:14 AM |
| See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
finance.yahoo.com - August 11 at 2:57 AM |
| ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Expected to Post Earnings of -$0.69 Per Share
www.americanbankingnews.com - August 10 at 8:22 PM |
| ACADIA Reports Strong Earnings Resulting From Accounting Change - Seeking Alpha
seekingalpha.com - August 10 at 4:52 PM |
| ACADIA Pharmaceuticals Inc. (ACAD) PT Set at $54.00 by Piper Jaffray Companies
www.americanbankingnews.com - August 10 at 9:08 AM |
| Acadia Shares Up Big On Strong Sales, Increased Confidence - Benzinga
www.benzinga.com - August 10 at 1:35 AM |
| 'Longing' for Acadia Pharmaceuticals? Here's How to Play It
finance.yahoo.com - August 9 at 8:34 PM |
 | Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today - Motley Fool
www.fool.com - August 9 at 3:33 PM |
| Edited Transcript of ACAD earnings conference call or presentation 8-Aug-17 9:00pm GMT
finance.yahoo.com - August 9 at 3:33 PM |
| Biotech Acadia Sends a Loud Message to the Market
finance.yahoo.com - August 9 at 3:33 PM |
| Why Acadia Pharma Is One of Wednesday’s Best Earnings Reports
finance.yahoo.com - August 9 at 3:33 PM |
ACADIA Pharmaceuticals (ACAD) Chart for Friday, September, 22, 2017
